http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 13:07:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Marvel+Biosciences+extends+private+placement+to+Quebec+investors/26949233.html <p>Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), a Calgary-based pre-clinical stage biotechnology company, has expanded its private placement to include investors resident in the Province of Quebec, according to a press release statement.</p> <p>The expansion builds on a private placement first announced on July 16, 2026. An amended and restated offering document dated August 19, 2026, is available in both English and French through the company's profile on the SEDAR+ website.</p> <p>The securities offered are not registered under the United States Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons absent an http://www.streetinsider.com/Equity+Offerings/Marvel+Biosciences+extends+private+placement+to+Quebec+investors/26949233.html Wed, 19 Aug 2026 13:07:09 -0400 MBCOF http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Expands+Private+Placement+to+Quebec/26949231.html <p>Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("<b>Marvel</b>" or the "<b>Company</b>") announces that it is expanding its previously announced private placement (<i>see July 16, 2026 press release</i>) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at https:// marvelbiotechnology.com/. Prospective investors should read this offering document before making an investment decision. The offering document is available in English and in French.</p><p>This news http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Expands+Private+Placement+to+Quebec/26949231.html Wed, 19 Aug 2026 13:06:00 -0400 MBCOF http://www.streetinsider.com/Newsfile/Marvel+Biosciences+Expands+Private+Placement+to+Quebec/26949231.html <p>Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("<b>Marvel</b>" or the "<b>Company</b>") announces that it is expanding its previously announced private placement (<i>see July 16, 2026 press release</i>) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at https:// marvelbiotechnology.com/. Prospective investors should read this offering document before making an investment decision. The offering document is available in English and in French.</p><p>This news http://www.streetinsider.com/Newsfile/Marvel+Biosciences+Expands+Private+Placement+to+Quebec/26949231.html Wed, 19 Aug 2026 13:06:00 -0400 MBCOF http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) reported preclinical data showing its lead drug candidate, MB-204, restored behavioral and cognitive function in a mouse model of Fragile X syndrome, according to a company press release.</p> <p>The study was conducted through the FRAXA Drug Validation Initiative, an independent program run in collaboration with the FRAXA Research Foundation. FMR1 knockout mice received oral doses of MB-204 once daily at low and high doses for approximately two weeks and were then retested two weeks after treatment ended.</p> <p>During the treatment period, both dose groups showed statistically significant improvements across multiple endpoints, including novel object http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html Wed, 05 Aug 2026 05:00:18 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) reported preclinical data showing its lead drug candidate, MB-204, restored behavioral and cognitive function in a mouse model of Fragile X syndrome, according to a company press release.</p> <p>The study was conducted through the FRAXA Drug Validation Initiative, an independent program run in collaboration with the FRAXA Research Foundation. FMR1 knockout mice received oral doses of MB-204 once daily at low and high doses for approximately two weeks and were then retested two weeks after treatment ended.</p> <p>During the treatment period, both dose groups showed statistically significant improvements across multiple endpoints, including novel object http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html Wed, 05 Aug 2026 05:00:18 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) reported preclinical data showing its lead drug candidate, MB-204, restored behavioral and cognitive function in a mouse model of Fragile X syndrome, according to a company press release.</p> <p>The study was conducted through the FRAXA Drug Validation Initiative, an independent program run in collaboration with the FRAXA Research Foundation. FMR1 knockout mice received oral doses of MB-204 once daily at low and high doses for approximately two weeks and were then retested two weeks after treatment ended.</p> <p>During the treatment period, both dose groups showed statistically significant improvements across multiple endpoints, including novel object http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html Wed, 05 Aug 2026 05:00:18 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) reported preclinical data showing its lead drug candidate, MB-204, restored behavioral and cognitive function in a mouse model of Fragile X syndrome, according to a company press release.</p> <p>The study was conducted through the FRAXA Drug Validation Initiative, an independent program run in collaboration with the FRAXA Research Foundation. FMR1 knockout mice received oral doses of MB-204 once daily at low and high doses for approximately two weeks and were then retested two weeks after treatment ended.</p> <p>During the treatment period, both dose groups showed statistically significant improvements across multiple endpoints, including novel object http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html Wed, 05 Aug 2026 05:00:18 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) reported preclinical data showing its lead drug candidate, MB-204, restored behavioral and cognitive function in a mouse model of Fragile X syndrome, according to a company press release.</p> <p>The study was conducted through the FRAXA Drug Validation Initiative, an independent program run in collaboration with the FRAXA Research Foundation. FMR1 knockout mice received oral doses of MB-204 once daily at low and high doses for approximately two weeks and were then retested two weeks after treatment ended.</p> <p>During the treatment period, both dose groups showed statistically significant improvements across multiple endpoints, including novel object http://www.streetinsider.com/FDA/Marvel+Biosciences+reports+MB-204+preclinical+results+in+Fragile+X+model/26869071.html Wed, 05 Aug 2026 05:00:18 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html <p align="justify">CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative in collaboration with the FRAXA Research Foundation.</p> <p align="justify">This announcement represents another significant milestone in the continued de-risking of Marvel Biosciences&apos; lead drug candidate, MB-204. By demonstrating <strong>statistically significant improvements in both behavioural and cognitive function http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Reports+Positive+Preclinical+Data+Demonstrating+MB-204+Reverses+Behavioural+and+Cognitive+Deficits+in+a+Mouse+Model+of+Fragile+X/26869066.html Wed, 05 Aug 2026 05:00:00 -0400 A.35960809 MBCOF MRVL O.04647377 O.46356335 http://www.streetinsider.com/Equity+Offerings/Marvel+Biosciences+plans+private+placement+of+up+to+%243M/26779543.html <p>Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) announced a non-brokered private placement offering of up to 20,000,000 units at $0.15 per unit, seeking gross proceeds of up to $3,000,000, according to a press release dated July 16, 2026.</p> <p>The offering has a minimum of 10,000,000 units for gross proceeds of $1,500,000. Each unit consists of one common share and one warrant, with each warrant exercisable at $0.20 per share beginning 61 days after closing and expiring one year from the closing date. The warrants may be accelerated if the volume weighted average trading price of the common shares on the TSX http://www.streetinsider.com/Equity+Offerings/Marvel+Biosciences+plans+private+placement+of+up+to+%243M/26779543.html Thu, 16 Jul 2026 16:01:13 -0400 MBCOF http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html <p>Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("<b>Marvel</b>" or the "<b>Company</b>") is pleased to announce that it intends to complete a non&#8208;brokered private placement offering (the "<b>Offering</b>") of units of the Company ("<b>Units</b>") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of 20,000,000 Units, for gross proceeds of up to $3,000,000.</p><p>Each Unit will consist of one common share of the Corporation ("<b>Common Share</b>") and one Common Share purchase warrant ("<b>Warrant</b>"). Each Warrant http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html Thu, 16 Jul 2026 16:00:00 -0400 MBCOF http://www.streetinsider.com/Newsfile/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html <p>Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("<b>Marvel</b>" or the "<b>Company</b>") is pleased to announce that it intends to complete a non&#8208;brokered private placement offering (the "<b>Offering</b>") of units of the Company ("<b>Units</b>") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of 20,000,000 Units, for gross proceeds of up to $3,000,000.</p><p>Each Unit will consist of one common share of the Corporation ("<b>Common Share</b>") and one Common Share purchase warrant ("<b>Warrant</b>"). Each Warrant http://www.streetinsider.com/Newsfile/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html Thu, 16 Jul 2026 16:00:00 -0400 MBCOF http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335